explore -WSS

explore

author：explore 2025-10-01 23:02:23 - browse：65

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare Advantage proposed rates disappoint insurers

focus

leisure time

WSS

Astronauts get first look at the spacecraft that will fly them around the moon

An Ebola outbreak presents a new mystery involving children

Biden praises World Series champion Astros for impact off the field during White House celebration

Vaccine advisory panel ACIP left half staffed by HHS

The Readout: Gilead, Bernie Sanders, and other pharma news

Sage's campaign to raise awareness of postpartum depression hits a nerve

focus

explore

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Judge rejects Trump's counterclaim against E. Jean Carroll

Medicare details structure of new drug price negotiation program

'Revelatory' study finds a smoking impact that remains after quitting

Moonlake's readout produced a cash windfall. Risks remain

CDC launches VaccineFinder tool to locate Covid

Supreme Court strikes down use of affirmative action

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Drug repurposing or repositioning? The language matters

Biden praises World Series champion Astros for impact off the field during White House celebration

Wikipedia

Private equity deals in Medicare Advantage declines

Biden report: The neurospychology of memory and aging

The Readout: Gilead, Bernie Sanders, and other pharma news

Gilead might be held responsible for not developing a drug

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

CDC launches VaccineFinder tool to locate Covid

hotspot

focus

leisure time

focus